

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Nyce J, W. :
Serial. No.: 09\093,972 : Group Art Unit: 1635
Filing Date: April 4, 2000 : Examiner: Dr. Janet Epps
For: **Composition, Formulations & Method for Prevention & Treatment of Diseases and Conditions Associated with Bronchoconstriction, Allergy(ies) & Inflammation**

STATEMENT UNDER 37 CFR 1.825(a) AND (b)

Assistant Commissioner for Patents
Washington D C 20231


Sir/Madam:

I, Viviana Amzel, hereby state that (1) the amendments, made in accordance with 37 CFR 1.825(a) and included in the substitute copy of the Sequence Listing filed herewith, are supported in the application as filed; (2) the enclosed substitute Sequence Listing includes no new matter and the sequences therein are, to the best of applicant's knowledge, the same, and (3) the substitute copy of the computer readable form, submitted in accordance with 37 CFR 1.825(b), is the same as the amended Sequence Listing.

Thus, applicant has fully met the requirements of 37 CFR 1.821 through 1.825 for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.


Respectfully submitted,
EPIGENESIS PHARMACEUTICALS, INC

April 4, 2001
Date


Viviana Amzel, Ph. D.
Reg. No. 30,930
Attorney for the Applicant

7 Clarke Drive
Cranbury, NJ 08512
609-409-3035 Legal Dept Ph.
413-254-9245 Legal Dept Fax
Vamzel@epigene.com
S:\Legal\00672\Dec - Seq Lst - 2001-03-21.doc

I hereby certify that this correspondence is being deposited with Federal Express and addressed to Examiner Janet Epps, U.S. Patent & Trademark Office, 1911 South Clark Street, Arlington, VA 22202-3503 by Dee Dee Sutherland on April 4, 2001.


SIGNATURE